Why the Medical Developments share price charged higher in October

Find out why the Medical Developments International Ltd (ASX: MVP) share price charged 17.7% higher as one of the October ASX winners.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medical Developments International Ltd (ASX: MVP) share price was one of the big gainers on the ASX last month.

The Aussie medical devices group had a huge month amid announcing a new CSIRO deal and several strong Penthrox updates.

a woman

Why did the Medical Developments share price charge higher?

The Medical Developments share price charged 17.7% higher to $5.85 per share by month-end. The big gains came in mid-October as the company updated the market on its Penthrox product.

Penthrox is an analgesic used by GPs, military forces and similar for emergency pain relief. It's commonly known as the "green whistle" due to the appearance of its hand-held inhaler.

The biggest boost for the Medical Developments share price came on 22 October after a key product update. The company's shares charged higher after Medical Developments reported strong Penthrox results from its European studies.

Just a day later on October 23, the Aussie company launched its signature product in Italy – the latest in a string of milestones.

This also triggered a US$2 million (A$2.9 million) payment from development partner Mundipharma which is expected in 2020.

In late October the company also signed a new Manufacturing Development Project with the CSIRO after 18 years of partnership. Medical Developments will invest up to $5 million over 5 years to develop new manufacturing technologies for pharmaceutical products.

Is November the time to buy?

The Medical Developments share price has outperformed the ASX 200 so far in 2019 after surging 39.44% higher.

The big red flag for me is just how expensive the company's shares are for what you're getting back in earnings.

The Medical Developments price-to-earnings (P/E) ratio is an astonishing 371x earnings, although these metrics can be flawed for growth companies.

Medical Developments has seen solid growth for the last 5 years as its shares have surged 371.43% to $5.94 per share.

However, I think I'd prefer to invest in a blue-chip name like CSL Ltd (ASX: CSL) given where we're at in the cycle right now.

Kenneth Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Medical Developments International Limited. The Motley Fool Australia has recommended Medical Developments International Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Three children wearing athletic short and singlets stand side by side on a running track wearing medals around their necks and standing with their hands on their hips.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a rough start to the trading week this Monday.

Read more »

A man looking at his laptop and thinking.
Broker Notes

Forget CBA shares and buy this ASX ETF: experts

Here's what experts are saying about these two investment options.

Read more »

Middle age caucasian man smiling confident drinking coffee at home.
Broker Notes

Buy, hold, sell: BHP, Guzman Y Gomez, and Pro Medicus shares

Are brokers bullish or bearish on these names? Let's find out.

Read more »

Red buy button on an Apple keyboard with a finger on it.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to buy these shares.

Read more »

Humanoid robot analysing the stock market, symbolising artificial intelligence shares.
Broker Notes

Up 109% since November, are Appen shares still a buy today?

A leading expert digs into the outlook for Appen shares amid the rise of AI.

Read more »

Paper aeroplane going down on a chart, symbolising a falling share price.
Travel Shares

Why Web Travel shares are sliding as fresh takeover hopes return

Web Travel shares sink as investors weigh CEO succession and takeover risk.

Read more »

Shot of a young businesswoman looking stressed out while working in an office.
Share Fallers

Why 4DMedical, Brainchip, Catapult, and Star Entertainment shares are falling today

These shares are starting the week in the red. But why>

Read more »

A white and black clock face is shown with three hands saying Time to Buy reflecting Citi's view that it's time to buy ASX 200 banks
Broker Notes

3 reasons to buy Pro Medicus shares today

Two leading investment analysts believe Pro Medicus shares are primed for a rebound.

Read more »